Colo205-luc Orthotopic Mouse Model Service for Colon Cancer

The Colo205-luc orthotopic mouse model pairs the BRAF^V600E-driven, microsatellite-stable molecular profile of human colorectal adenocarcinoma with constitutive firefly luciferase expression, enabling non-invasive, quantitative monitoring of tumor establishment, local progression, and therapeutic response within the native cecal wall architecture. Alfa Cytology engineers this advanced bioluminescent xenograft system with validated cell line authentication, precision surgical implantation, and calibrated IVIS imaging protocols, delivering longitudinal tumor kinetics data and comprehensive endpoint histopathology to accelerate your BRAF-targeted colon cancer drug discovery program.

Overview of Colo205-luc Orthotopic Mouse Model for Colon Cancer

The Colo205-luc cell line is a genetically engineered derivative of the parental Colo205 human colorectal adenocarcinoma line, stably transfected with a constitutive firefly luciferase reporter construct that enables sensitive, substrate-dependent bioluminescent signal detection. The parental line was originally isolated in 1975 from the ascitic fluid of a 70-year-old male patient with Dukes Grade D metastatic disease and is defined by a homozygous BRAF^V600E activating mutation, biallelic APC truncation, mutant TP53 (p.Arg248Trp), wild-type KRAS, and microsatellite stable (MSS) status—placing it within the CMS3/iCMS3-MSS molecular spectrum. The addition of luciferase reporter functionality transforms Colo205 into a dynamic optical imaging platform: as few as 5,000 cells emit detectable photon flux in vitro, and in vivo tumor burdens can be quantified repeatedly without interim animal sacrifice, yielding continuous growth curves and early detection of therapeutic efficacy or resistance emergence.

Fig 1. Representative IVIS images of mice with orthotopic implants of COLO205-luc after 3 days of implantation in cecum. (Sudha, Thangirala, et al., 2020)

When established as an orthotopic xenograft within the murine cecal wall, Colo205-luc recapitulates the serosal-submucosal tumor-stromal interface of human colonic carcinoma. The cecal pouch implantation technique—wherein subcutaneous donor tumor fragments are enveloped within the cecal tip or cell suspensions are injected into the subserosal muscularis—promotes localized tumor development with regional lymphatic spread patterns that mirror early-stage clinical disease. Bioluminescence imaging captures tumor signal as early as 3–5 days post-implantation, with exponential growth typically observed over 2–3 weeks. This optical tracking capability distinguishes true tumor regression from pseudoresponse, identifies occult metastatic seeding, and enables cohort randomization based on objective photon flux thresholds rather than subjective palpation—critical advantages for evaluating BRAF/MEK inhibitors, EGFR combination regimens, and novel targeted agents in a preclinical setting that demands both anatomical fidelity and quantitative precision.

Cell Line Information: Colo205-luc

Colo205-luc is a luciferase-reporter derivative of the human colorectal adenocarcinoma Colo205 cell line, engineered for constitutive firefly luciferase expression and validated for bioluminescence imaging applications. The following table summarizes its biological origin, molecular profile, reporter characteristics, and culture specifications:

Our Services

Alfa Cytology delivers turnkey Colo205-luc orthotopic model services spanning authenticated luciferase-stable cell bank maintenance, cecal wall surgical implantation with validated tumor fragment envelopment or direct injection techniques, serial bioluminescence imaging on calibrated IVIS platforms, and terminal multimodal endpoint analysis. Our scientists ensure each production batch is STR-verified, mycoplasma-negative, and phenotypically authenticated for BRAF^V600E expression and luciferase activity before surgical use. We support BRAF/MEK inhibitor programs, EGFR combination studies, and nanoparticle delivery assessments with flexible study designs, pharmacokinetic integration, and GLP-compliant documentation packages tailored to your preclinical milestones.

Workflow of Colo205-luc Orthotopic Mouse Model Construction

Construction of the Colo205-luc orthotopic model integrates reporter cell line quality assurance, sterile surgical technique, and standardized bioluminescence imaging calibration to ensure reproducible engraftment and quantitative tumor tracking. Our protocol is optimized for consistent optical signal fidelity, minimal perioperative loss, and robust therapeutic readouts. The procedure unfolds as follows:

1. Master Cell Bank Revival and Reporter Validation: Colo205-luc master stocks are revived and expanded in antibiotic-free RPMI 1640 medium. Each production lot undergoes STR profiling against the reference database, mycoplasma PCR screening, BRAF^V600E allele-specific validation, and in vitro luciferase functional assay (Bright-Glo or equivalent) to confirm reporter expression levels and signal linearity prior to surgical use.
2. Subcutaneous Donor Tumor Generation (Fragment Route): For the tumor fragment grafting approach, Colo205-luc cells (0.2 x 10⁶ in 100 μL 50% Matrigel) are injected subcutaneously into the right front axilla of donor athymic nude mice. Four implants per mouse maximize donor tissue yield. Tumors are harvested at ~100–150 mm³ (typically 2–3 weeks), necrotic tissue is excised, and fragments are sectioned to 0.15 mg pieces using a sterile scalpel with weight verified on a precision microbalance (±0.05 mg deviation).
3. Recipient Mouse Preparation and Anesthesia: Female athymic nude mice (BALB/c nu/nu, 5–7 weeks, 18–22 g) are acclimated for 7 days under SPF barrier conditions. General anesthesia is induced with 1–2% isoflurane in medical oxygen via nose cone. The ventral abdomen is shaved, cleansed with povidone-iodine and 70% ethanol, and draped sterilely.
4. Cecal Wall Orthotopic Implantation: Two validated techniques are employed. Technique A (cecal pouch envelopment): a small pouch is created at the cecal tip, a 0.15 mg tumor fragment is inserted, and the pouch is secured with 3-0 silk sutures. Technique B (direct cell injection): a 30-gauge Hamilton micro-syringe delivers 1 x 10⁶ cells in 30 μL PBS/Matrigel into the subserosal muscularis of the cecal wall. The cecum is returned to the peritoneal cavity, and the abdominal wall and skin are closed with 5-0 absorbable sutures or surgical staples.
5. Post-Operative Recovery and Clinical Surveillance: Mice recover on a heated pad until fully ambulatory. Post-operative analgesia (buprenorphine 0.05–0.1 mg/kg, s.c.) is administered per IACUC guidelines. Daily monitoring for 7–10 days assesses wound integrity, body weight, food intake, and abdominal distension. Humane endpoints include >20% body weight loss, wound dehiscence, or signs of severe distress.
6. Baseline Bioluminescence Imaging and Cohort Enrollment: Starting 3–5 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS Spectrum system. Baseline total flux (photons/sec) is recorded for each animal. Mice with confirmed bioluminescent signal are enrolled; those without detectable engraftment are excluded. Cohorts are randomized once mean tumor burden reaches a predefined threshold (e.g., 1–5 x 10⁶ photons/sec).
7. Therapeutic Intervention and Longitudinal Bioluminescence Monitoring: Test articles are administered per protocol via oral gavage, intravenous, intraperitoneal, or subcutaneous routes. Tumor burden is monitored via bioluminescence imaging twice weekly; body weights and clinical observations are recorded three times weekly. Blood samples may be collected for pharmacokinetic or CEA biomarker analysis. The optical readout enables early detection of treatment response, typically within 24–72 hours for cytotoxic agents.
8. Necropsy, Tumor Harvest, and Multimodal Endpoint Analysis: At study termination, mice are humanely euthanized. The primary cecal tumor is excised, weighed, photographed, and dimensions recorded. The abdominal cavity is inspected for peritoneal carcinomatosis. Metastatic target organs (liver, lung, mesenteric lymph nodes) are harvested. Tissues are fixed in 10% neutral buffered formalin for H&E histology, or snap-frozen for molecular analysis. Immunohistochemistry for Ki-67, cleaved caspase-3, CD31, BRAFV600E, phospho-ERK1/2, and CEA provides mechanistic insight into proliferation, apoptosis, angiogenesis, MAPK suppression, and tumor differentiation.

Fig 2. Colo205-luc Orthotopic Mouse Model construction workflow.

Case Study-Colo205-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, the Colo205-luc orthotopic model was deployed to evaluate the anti-tumor efficacy of a resveratrol-loaded polymeric nanoformulation versus free drug in BRAF-mutant colorectal cancer. Colo205-luc cells were first grown as subcutaneous donor tumors, and equal-sized fragments were implanted into cecal pouches of athymic nude mice. Bioluminescence imaging on day 3 confirmed successful engraftment across all animals. Mice were then randomized to receive daily treatments with vehicle, void nanoparticles, free resveratrol (2 mg/kg), or nano-encapsulated resveratrol (2 mg/kg) for 3 weeks. Longitudinal IVIS imaging revealed progressive bioluminescent signal attenuation in the nanoformulation group compared to modest suppression with free drug and continued exponential growth in vehicle controls. At necropsy, the nanoformulation cohort exhibited significantly reduced primary cecal tumor weight and diminished hemoglobin content—a surrogate marker of angiogenic vasculature—compared to both free resveratrol and vehicle groups. Ex vivo bioluminescence of excised tumors corroborated the in vivo imaging data, with photon flux reductions aligning closely with tumor mass measurements. These results demonstrate how the Colo205-luc orthotopic platform integrates real-time optical tracking with terminal histopathological and angiogenic endpoint analysis to rigorously benchmark novel drug delivery systems against conventional formulations in a single preclinical study.

Why Choose Alfa Cytology?

Preclinical programs targeting BRAF-mutant colorectal cancer require a model that combines molecular fidelity, anatomical relevance, and quantitative longitudinal readouts. Alfa Cytology structures its Colo205-luc orthotopic service around these requirements, delivering capabilities that distinguish our offering in the CRO landscape:

• We maintain authenticated, low-passage Colo205-luc master and working cell banks with documented STR profiles, routine mycoplasma surveillance, BRAF^V600E allele-specific qPCR validation, and serial luciferase activity QC—ensuring reporter fidelity and genetic stability across every study batch.
• Our surgical team is proficient in both cecal pouch tumor fragment envelopment and direct subserosal cell injection techniques, achieving consistent engraftment with bioluminescence signal detectable within 3–5 days and minimal perioperative mortality.
• Bioluminescence imaging is conducted on calibrated IVIS Spectrum platforms with standardized D-luciferin dosing, exposure times, and ROI analysis protocols, yielding photon flux data with inter-study reproducibility suitable for cross-study meta-analysis.
• The optical reporter enables objective, non-invasive cohort randomization based on quantified tumor burden rather than palpation, eliminating enrollment bias and improving statistical power—particularly critical for BRAF inhibitor studies where early tumor regression is a key efficacy endpoint.
• We offer integrated multimodal endpoint analysis as standard, including digital whole-slide H&E pathology, IHC-based MAPK pathway biomarker assessment (phospho-ERK1/2, BRAF^V600E), CEA quantification, and tumor hemoglobin content analysis for angiogenic evaluation.
• Study designs are fully modular—we accommodate nanoparticle delivery assessments, combination regimen matrices with dose-escalation arms, and pharmacokinetic bridging studies, with GLP-compliant documentation available to support IND-enabling packages and regulatory submissions.

Contact Us

If your colorectal cancer research program demands a BRAF-mutant orthotopic model with real-time bioluminescent tracking, quantitative longitudinal monitoring, and deep molecular endpoint characterization, we invite you to reach out to us for a confidential project discussion. The scientific team at Alfa Cytology is prepared to architect a customized Colo205-luc orthotopic study aligned with your therapeutic mechanism, compound formulation, and regulatory roadmap. Contact us today to request a detailed proposal, feasibility assessment, and projected timeline—let us advance your BRAF-targeted pipeline with rigorous, publication-ready preclinical data.

For research use only. Not intended for any clinical use.